威廉亚洲官网
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
威廉亚洲博彩公司
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床威廉亚洲博彩公司
医学计算与公式
ICD-10/ICD-11疾病编码
医迅达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci williamhill asia 搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
#Guselkumab#
20篇内容 | 1540人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=d8e783268f, topicName=Guselkumab, introduction=Guselkumab, content=null, image=null, comments=20, allHits=1540, url=https://h5.medsci.cn/topic?id=8326, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=27573, tagList=[TagDto(tagId=27573, tagName=Guselkumab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2189296, encodeId=fd702189296bc, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a> <a href='/topic/show?id=dded1115324c' target=_blank style='color:#2F92EE;'>#中重度活动性溃疡性结肠炎#</a> <a href='/topic/show?id=68b311150446' target=_blank style='color:#2F92EE;'>#ECCO 2024#</a>, objectTitle=ECCO 2024:Guselkumab 可改善中重度活动性溃疡性结肠炎患者的生活质量, objectType=article, longId=814760, objectId=f144814e609a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240225/1708857943062_8624274.png, objectUrl=/article/show_article.do?id=f144814e609a, replyNumber=0, likeNumber=90, createdTime=2024-02-25, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f144814e609a, moduleTitle=ECCO 2024:Guselkumab 可改善中重度活动性溃疡性结肠炎患者的生活质量, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f144814e609a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2089207, encodeId=3e46208920e3a, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>治疗<a href='/topic/show?id=5a64966325c' target=_blank style='color:#2F92EE;'>#银屑病关节炎#</a>的疗效比较:<a href='/topic/show?id=9746104e8634' target=_blank style='color:#2F92EE;'>#系统文献综述#</a>和<a href='/topic/show?id=e48c10442368' target=_blank style='color:#2F92EE;'>#网状meta#</a>分析的最新进展, objectTitle=Rheumatology:Guselkumab治疗银屑病关节炎的疗效比较:系统文献综述和网络Meta分析的最新进展, objectType=article, longId=740091, objectId=386ae40091ce, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220920/1663605734122_2269929.png, objectUrl=/article/show_article.do?id=386ae40091ce, replyNumber=0, likeNumber=104, createdTime=2022-09-20, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=386ae40091ce, moduleTitle=Rheumatology:Guselkumab治疗银屑病关节炎的疗效比较:系统文献综述和网络Meta分析的最新进展, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=386ae40091ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349875, encodeId=852213498e5ec, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=JEADV:Guselkumab治疗银屑病1年效果研究, objectType=article, longId=728037, objectId=368ee28037a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=368ee28037a5, replyNumber=0, likeNumber=61, createdTime=2022-05-29, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=368ee28037a5, moduleTitle=JEADV:Guselkumab治疗银屑病1年效果研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=368ee28037a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349874, encodeId=58ab13498e4c4, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=Arthritis Rheumatol:单克隆抗体Guselkumab治疗活动性银屑病的长期疗效和安全性, objectType=article, longId=301766, objectId=95c3301e667c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95c3301e667c, replyNumber=0, likeNumber=64, createdTime=2022-03-28, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95c3301e667c, moduleTitle=Arthritis Rheumatol:单克隆抗体Guselkumab治疗活动性银屑病的长期疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=95c3301e667c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349873, encodeId=364c13498e3c4, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=Br J Dermatol:ixekizumab与guselkumab治疗中重度斑块状银屑病的疗效和安全性, objectType=article, longId=292150, objectId=0b012921503e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b012921503e, replyNumber=0, likeNumber=61, createdTime=2021-12-19, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b012921503e, moduleTitle=Br J Dermatol:ixekizumab与guselkumab治疗中重度斑块状银屑病的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0b012921503e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349872, encodeId=9f0d13498e236, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=JAAD:古塞库单抗(Guselkumab)连续五年治疗中度至重度银屑病的安全性分析, objectType=article, longId=221468, objectId=b9382214685e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9382214685e, replyNumber=0, likeNumber=57, createdTime=2021-12-04, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9382214685e, moduleTitle=JAAD:古塞库单抗(Guselkumab)连续五年治疗中度至重度银屑病的安全性分析, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b9382214685e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349871, encodeId=4c0413498e121, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=Lancet Rheumatology:Guselkumab对活动性银屑病关节炎和骶髂关节炎患者中轴受累的疗效, objectType=article, longId=219178, objectId=43202191e830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43202191e830, replyNumber=0, likeNumber=75, createdTime=2021-10-26, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43202191e830, moduleTitle=Lancet Rheumatology:Guselkumab对活动性银屑病关节炎和骶髂关节炎患者中轴受累的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=43202191e830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349870, encodeId=e82a13498e0bf, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=欧盟委员会批准了TREMFYA®(guselkumab)治疗活动性银屑病关节炎(PsA), objectType=article, longId=203779, objectId=0bb5203e7985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bb5203e7985, replyNumber=0, likeNumber=60, createdTime=2020-11-28, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bb5203e7985, moduleTitle=欧盟委员会批准了TREMFYA®(guselkumab)治疗活动性银屑病关节炎(PsA), moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0bb5203e7985)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349869, encodeId=107b13498695a, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=TREMFYA(guselkumab)治疗成人银屑病关节炎:显著减少了疲劳症状, objectType=article, longId=203134, objectId=b12e2031349b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12e2031349b, replyNumber=0, likeNumber=114, createdTime=2020-11-10, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12e2031349b, moduleTitle=TREMFYA(guselkumab)治疗成人银屑病关节炎:显著减少了疲劳症状, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b12e2031349b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349868, encodeId=f636134986824, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=TREMFYA(guselkumab)治疗活动性银屑病关节炎(PsA):已获得CHMP的积极意见, objectType=article, longId=202280, objectId=18ae2022800c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ae2022800c, replyNumber=0, likeNumber=66, createdTime=2020-10-21, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ae2022800c, moduleTitle=TREMFYA(guselkumab)治疗活动性银屑病关节炎(PsA):已获得CHMP的积极意见, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=18ae2022800c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349867, encodeId=4ba4134986e4a, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA(guselkumab), objectType=article, longId=197593, objectId=979d19e59394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979d19e59394, replyNumber=0, likeNumber=48, createdTime=2020-07-17, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979d19e59394, moduleTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA(guselkumab), moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=979d19e59394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349866, encodeId=cf541349866b3, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=Lancet:白细胞介素23单抗Guselkumab治疗活动性银屑病关节炎, objectType=article, longId=191455, objectId=80f2191455c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80f2191455c6, replyNumber=0, likeNumber=60, createdTime=2020-04-06, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80f2191455c6, moduleTitle=Lancet:白细胞介素23单抗Guselkumab治疗活动性银屑病关节炎, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=80f2191455c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349865, encodeId=9d3213498653b, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=Lancet:Guselkumab用于活动性银屑病性关节炎, objectType=article, longId=190128, objectId=66fe19012824, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66fe19012824, replyNumber=0, likeNumber=64, createdTime=2020-03-18, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66fe19012824, moduleTitle=Lancet:Guselkumab用于活动性银屑病性关节炎, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=66fe19012824)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349864, encodeId=232613498642d, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=Lancet:Guselkumab vs Secukinumab用于中重度银屑病, objectType=article, longId=177645, objectId=b4301e764526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4301e764526, replyNumber=0, likeNumber=68, createdTime=2019-08-16, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4301e764526, moduleTitle=Lancet:Guselkumab vs Secukinumab用于中重度银屑病, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b4301e764526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349863, encodeId=b1de134986362, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=美国FDA批准新型TREMFYA(guselkumab)制剂治疗成人中度至重度斑块型银屑病, objectType=article, longId=161432, objectId=c21f16143225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c21f16143225, replyNumber=0, likeNumber=52, createdTime=2019-03-02, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c21f16143225, moduleTitle=美国FDA批准新型TREMFYA(guselkumab)制剂治疗成人中度至重度斑块型银屑病, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c21f16143225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349862, encodeId=54cb1349862d3, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=MorphoSys宣布开始3期试验(PROTOSTAR)评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, objectType=article, longId=149686, objectId=d1891496860a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1891496860a, replyNumber=0, likeNumber=61, createdTime=2018-09-28, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1891496860a, moduleTitle=MorphoSys宣布开始3期试验(PROTOSTAR)评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d1891496860a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349861, encodeId=6a6c13498616d, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=ICER:Guselkumab和Risankizumab靶向治疗斑块状银屑病具有更高的临床益处, objectType=article, longId=145944, objectId=6e0014594413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e0014594413, replyNumber=0, likeNumber=54, createdTime=2018-08-07, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e0014594413, moduleTitle=ICER:Guselkumab和Risankizumab靶向治疗斑块状银屑病具有更高的临床益处, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6e0014594413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349860, encodeId=727113498602f, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=DRUGS:Guselkumab获得首次全球认证, objectType=article, longId=123787, objectId=5178123e871f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5178123e871f, replyNumber=0, likeNumber=66, createdTime=2017-12-19, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5178123e871f, moduleTitle=DRUGS:Guselkumab获得首次全球认证, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5178123e871f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349859, encodeId=ae701349859c3, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=Br J Dermatol:Guselkumab治疗不同亚群的中度至重度斑块型银屑病,疗效依然较优, objectType=article, longId=114695, objectId=84bc114695d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84bc114695d0, replyNumber=0, likeNumber=52, createdTime=2017-09-30, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84bc114695d0, moduleTitle=Br J Dermatol:Guselkumab治疗不同亚群的中度至重度斑块型银屑病,疗效依然较优, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=84bc114695d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1349858, encodeId=8229134985838, content=<a href='/topic/show?id=d8e783268f' target=_blank style='color:#2F92EE;'>#Guselkumab#</a>, objectTitle=NEJM:新药guselkumab能有效控制中重度制斑块性银屑病, objectType=article, longId=53203, objectId=99415320328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99415320328, replyNumber=0, likeNumber=0, createdTime=2015-07-12, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99415320328, moduleTitle=NEJM:新药guselkumab能有效控制中重度制斑块性银屑病, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=99415320328)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
williamhill asia 话题小助手
关注
已关注
Guselkumab
2020-05-29
williamhill asia 管理员
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
#中重度活动性溃疡性结肠炎#
#ECCO 2024#
ECCO 2024:Guselkumab 可改善中重度活动性溃疡性结肠炎患者的生活质量
90
0
2024-02-25发表于上海
回复
小小医者
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
治疗
#银屑病关节炎#
的疗效比较:
#系统文献综述#
和
#网状meta#
分析的最新进展
Rheumatology:Guselkumab治疗银屑病关节炎的疗效比较:系统文献综述和网络Meta分析的最新进展
104
0
2022-09-20
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
JEADV:Guselkumab治疗银屑病1年效果研究
61
0
2022-05-29
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
Arthritis Rheumatol:单克隆抗体Guselkumab治疗活动性银屑病的长期疗效和安全性
64
0
2022-03-28
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
Br J Dermatol:ixekizumab与guselkumab治疗中重度斑块状银屑病的疗效和安全性
61
0
2021-12-19
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
JAAD:古塞库单抗(Guselkumab)连续五年治疗中度至重度银屑病的安全性分析
57
0
2021-12-04
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
Lancet Rheumatology:Guselkumab对活动性银屑病关节炎和骶髂关节炎患者中轴受累的疗效
75
0
2021-10-26
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
欧盟委员会批准了TREMFYA®(guselkumab)治疗活动性银屑病关节炎(PsA)
60
0
2020-11-28
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
TREMFYA(guselkumab)治疗成人银屑病关节炎:显著减少了疲劳症状
114
0
2020-11-10
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
TREMFYA(guselkumab)治疗活动性银屑病关节炎(PsA):已获得CHMP的积极意见
66
0
2020-10-21
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA(guselkumab)
48
0
2020-07-17
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
Lancet:白细胞介素23单抗Guselkumab治疗活动性银屑病关节炎
60
0
2020-04-06
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
Lancet:Guselkumab用于活动性银屑病性关节炎
64
0
2020-03-18
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
Lancet:Guselkumab vs Secukinumab用于中重度银屑病
68
0
2019-08-16
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
美国FDA批准新型TREMFYA(guselkumab)制剂治疗成人中度至重度斑块型银屑病
52
0
2019-03-02
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
MorphoSys宣布开始3期试验(PROTOSTAR)评估IL-23单抗Guselkumab对银屑病儿童患者的疗效
61
0
2018-09-28
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
ICER:Guselkumab和Risankizumab靶向治疗斑块状银屑病具有更高的临床益处
54
0
2018-08-07
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
DRUGS:Guselkumab获得首次全球认证
66
0
2017-12-19
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
Br J Dermatol:Guselkumab治疗不同亚群的中度至重度斑块型银屑病,疗效依然较优
52
0
2017-09-30
回复
tamgche
(审核中...)
关注
已关注
前往app查看评论内容
#Guselkumab#
NEJM:新药guselkumab能有效控制中重度制斑块性银屑病
0
0
2015-07-12
回复
共21条
首页
上一页
下一页
尾页
页码:
1
/2页
20条/页
扫描二维码下载williamhill asia 医学APP
科室
订阅+
更多科室
工具
服务